Patents by Inventor Michael Sturzl

Michael Sturzl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for detecting an increased risk or incidence of colorectal cancer
    Patent number: 11970744
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: April 30, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
    Publication number: 20210317536
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Application
    Filed: June 14, 2021
    Publication date: October 14, 2021
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for detecting an increased risk or incidence of colorectal cancer
    Patent number: 11066710
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: July 20, 2021
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
    Publication number: 20190169699
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 6, 2019
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for detecting an increased risk or incidence of colorectal cancer
    Patent number: 10253372
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 9, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
    Publication number: 20170002429
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
    Publication number: 20150299799
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Application
    Filed: September 30, 2013
    Publication date: October 22, 2015
    Inventors: Michael STURZL, Roland S. CRONER, Andres KONRAD
  • Elisa method for the detection of guanylate binding protein 1 (gbp-1)
    Patent number: 7498144
    Abstract: A method for the identification and/or quantification of GBP-1 or fragments of this protein in the culture supernatant of a tissue sample, a body fluid sample or a sample from a cell culture supernatant is described.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: March 3, 2009
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Michael Stürzl, Clara Lubeseder-Martellato, Eric Guenzi, Elisabeth Kremmer
  • Elisa method for the detection of guanylate binding protein 1 (gbp-1)
    Publication number: 20060154316
    Abstract: A method for the identification and/or quantification of GBP-1 or fragments of this protein in the culture supernatant of a tissue sample, a body fluid sample or a sample from a cell culture supernatant is described.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 13, 2006
    Applicant: GSF-Forschungszentrum für Umwelt und Gesundheit GmbH
    Inventors: Michael Sturzl, Clara Lubeseder-Martellato, Eric Guenzi, Elisabeth Kremmer
  • Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
    Publication number: 20060025362
    Abstract: The present invention relates to a recombinant protein consisting of Guanylate Binding Protein-1 (GBP-1), or one or more functional parts thereof, linked to a shuttle protein. The present invention also relates to an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said vector comprising said gene or parts thereof in sense or antisense orientation into cells can be used to induce phenotypical changes of said cells and can, thus, be used for modulation of cell differentiation. Additionally, the present invention provides, inter alia, a method for determination of the stage of cellular differention by using GBP-1 gene expression as a marker.
    Type: Application
    Filed: February 16, 2005
    Publication date: February 2, 2006
    Inventors: Michael Sturzl, Emmanuelle Cornali
  • Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
    Patent number: 6894157
    Abstract: The present invention relates to an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said vector comprising said gene or parts thereof in sense or antisense orientation into cells can be used to induce phenotypical changes of said cells and can, thus, be used for modulation of cell differentiation. Additionally, the present invention provides, inter alia, a method for determination of the stage of cellular differention by using GBP-1 gene expression as a marker.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: May 17, 2005
    Inventors: Michael Stürzl, Emmanuelle Cornali
  • Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
    Publication number: 20020115138
    Abstract: The present invention relates to an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said vector comprising said gene or parts thereof in sense or antisense orientation into cells can be used to induce phenotypical changes of said cells and can, thus, be used for modulation of cell differentiation. Additionally, the present invention provides, inter alia, a method for determination of the stage of cellular differention by using GBP-1 gene expression as a marker.
    Type: Application
    Filed: February 23, 2001
    Publication date: August 22, 2002
    Applicant: Bavarian Nordic Research Institute A/S
    Inventors: Michael Sturzl, Emmanuelle Cornali